About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Col1a1tm1(tetO-Fos)Wag
targeted mutation 1, Erwin F Wagner
MGI:5555845
Summary 3 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
 		Col1a1tm1(tetO-Fos)Wag/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Alb1-cre)7Gsc/0 		involves: 129 * C57BL/6 * FVB/N MGI:5586562
cx2
 		Col1a1tm1(tetO-Fos)Wag/Col1a1+
Rag1tm1Mom/Rag1tm1Mom
Tg(KRT5-rtTA)T2D6Sgkd/0 		involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6 * FVB/N MGI:5555860
cx3
 		Col1a1tm1(tetO-Fos)Wag/Col1a1+
Tg(KRT5-rtTA)T2D6Sgkd/0 		involves: 129S4/SvJae * C57BL/6 * FVB/N MGI:5555858


Genotype
MGI:5586562
cn1
Allelic
Composition		 Col1a1tm1(tetO-Fos)Wag/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Alb1-cre)7Gsc/0
Genetic
Background		 involves: 129 * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-Fos)Wag mutation (0 available); any Col1a1 mutation (160 available)
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy mutation (5 available); any Gt(ROSA)26Sor mutation (942 available)
Tg(Alb1-cre)7Gsc mutation (1 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:210545 )
• doxycycline-treated mice develop lethal liver dysplasia

liver/biliary system
abnormal liver morphology ( J:210545 )
• doxycycline-treated mice develop lethal liver dysplasia




Genotype
MGI:5555860
cx2
Allelic
Composition		 Col1a1tm1(tetO-Fos)Wag/Col1a1+
Rag1tm1Mom/Rag1tm1Mom
Tg(KRT5-rtTA)T2D6Sgkd/0
Genetic
Background		 involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-Fos)Wag mutation (0 available); any Col1a1 mutation (160 available)
Rag1tm1Mom mutation (49 available); any Rag1 mutation (120 available)
Tg(KRT5-rtTA)T2D6Sgkd mutation (1 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
integument
integument phenotype ( J:201145 )
N
• doxycycline-treated mice exhibit normal keratinocyte proliferation and activation
skin lesions ( J:201145 )
• in doxycycline-treated mice but smaller than in mice with wild-type Rag1
skin hyperplasia ( J:201145 )
• in doxycycline-treated mice but less so than in mice with wild-type Rag1




Genotype
MGI:5555858
cx3
Allelic
Composition		 Col1a1tm1(tetO-Fos)Wag/Col1a1+
Tg(KRT5-rtTA)T2D6Sgkd/0
Genetic
Background		 involves: 129S4/SvJae * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-Fos)Wag mutation (0 available); any Col1a1 mutation (160 available)
Tg(KRT5-rtTA)T2D6Sgkd mutation (1 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:201145 )
• after doxycycline treatment

integument
increased keratinocyte proliferation ( J:201145 )
• with increased survival in doxycycline-treated mice
skin inflammation ( J:201145 )
• in doxycycline-treated mice
alopecia ( J:201145 )
• after doxycycline treatment
absent hair follicles ( J:201145 )
• in doxycycline-treated mice
hyperkeratosis ( J:201145 )
• cornified epidermis in affected skin of doxycycline-treated mice
parakeratosis ( J:201145 )
• in doxycycline-treated mice
epidermal hyperplasia ( J:201145 )
• in doxycycline-treated mice
• however, MMP inhibitor impairs hyperplasia
skin lesions ( J:201145 )
• dry and scaly lesions on the affected skin of doxycycline-treated mice
skin hyperplasia ( J:201145 )
• in doxycycline-treated mice
thick skin ( J:201145 )
• affected skin of doxycycline-treated mice

immune system
immune system phenotype ( J:201145 )
N
• doxycycline-treated mice exhibit normal spleen weight
increased granulocyte number ( J:201145 )
• in the skin of doxycycline-treated mice
increased CD4-positive, alpha-beta T cell number ( J:201145 )
• in the skin of doxycycline-treated mice
• however, doxycycline withdrawal restores CD4+ T cell numbers
skin inflammation ( J:201145 )
• in doxycycline-treated mice

neoplasm
increased incidence of tumors by chemical induction ( J:201145 )
• doxycycline-treated mice exposed to DMBA/TPA develop papillomas at 8 weeks that become ulcerative at 11 weeks
• however, sulindac treatment reduces the number and size of tumors
increased papilloma incidence ( J:201145 )
• doxycycline-treated mice exposed to DMBA/TPA develop papillomas at 8 weeks that become ulcerative at 11 weeks

growth/size/body
decreased body size ( J:201145 )
• after doxycycline treatment

digestive/alimentary system
abnormal forestomach morphology ( J:201145 )
• mild phenotype in doxycycline-treated mice

homeostasis/metabolism
increased incidence of tumors by chemical induction ( J:201145 )
• doxycycline-treated mice exposed to DMBA/TPA develop papillomas at 8 weeks that become ulcerative at 11 weeks
• however, sulindac treatment reduces the number and size of tumors

cellular
increased keratinocyte proliferation ( J:201145 )
• with increased survival in doxycycline-treated mice

hematopoietic system
increased granulocyte number ( J:201145 )
• in the skin of doxycycline-treated mice
increased CD4-positive, alpha-beta T cell number ( J:201145 )
• in the skin of doxycycline-treated mice
• however, doxycycline withdrawal restores CD4+ T cell numbers




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
04/23/2024
MGI 6.23 		The Jackson Laboratory